Literature DB >> 12431443

Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure.

George W Booz1, Jonathan N E Day, Kenneth M Baker.   

Abstract

Recent studies have shown that the JAK-STAT signaling pathway plays a central role in cardiac pathophysiology. JAK-STAT signaling has been implicated in pressure overload-induced cardiac hypertrophy and remodeling, ischemic preconditioning, and ischemia/reperfusion-induced cardiac dysfunction. The different STAT family members expressed in cardiac myocytes appear to be linked to different, and at times, opposite responses, such as cell growth/survival and apoptosis. Thus, differential activation and/or selective inhibition of the STAT proteins by agonists for G-protein coupled receptors, such as angiotensin II, may contribute to cardiac dysfunction during ischemia and heart failure. In addition, JAK-STAT signaling may represent one limb of an autocrine loop for angiotensin II generation, that serves to amplify the actions of angiotensin II on cardiac muscle. The purpose of this article is to provide an overview of recent findings that have been made for JAK-STAT signaling in cardiac myocytes and to highlight some unresolved issues for future investigation. The central focus of this review is on recent studies suggesting that modulation or activation of JAK-STAT signaling by ANG II has pathological consequences for heart function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431443     DOI: 10.1006/jmcc.2002.2076

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  45 in total

1.  JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma.

Authors:  Zhenbing You; Dafu Xu; Jian Ji; Wei Guo; Weiguo Zhu; Jingdong He
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

3.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

Review 4.  A multidimensional sight on cardiac failure: uncovered from structural to molecular level.

Authors:  Vijay Urmaliya; Gustavo Franchelli
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

5.  IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart.

Authors:  Indroneal Banerjee; John W Fuseler; Arti R Intwala; Troy A Baudino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-20       Impact factor: 4.733

6.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

Review 7.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

8.  17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload.

Authors:  Richard D Patten; Isaac Pourati; Mark J Aronovitz; Alawi Alsheikh-Ali; Sarah Eder; Thomas Force; Michael E Mendelsohn; Richard H Karas
Journal:  J Card Fail       Date:  2008-04       Impact factor: 5.712

9.  Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency.

Authors:  Qingyun Qin; Chen Qu; Ting Niu; Huimei Zang; Lei Qi; Linmao Lyu; Xuejun Wang; Mitzi Nagarkatti; Prakash Nagarkatti; Joseph S Janicki; Xing Li Wang; Taixing Cui
Journal:  Hypertension       Date:  2015-11-16       Impact factor: 10.190

10.  Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes.

Authors:  LiJun Wu; LianYou Zhao; QiangSun Zheng; FuJun Shang; XianMei Wang; LiFeng Wang; Bing Lang
Journal:  Mol Cell Biochem       Date:  2006-03-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.